Ironwood Pharmaceuticals Inc (IRWD)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $799.61M
Last updated: Nov 17, 2026 at 11:06 AM ET
Ironwood Pharmaceuticals Inc (IRWD) Earnings: Report Dates and Results
Ironwood Pharmaceuticals (IRWD) is expected to report earnings on Feb 23, 2027. In the quarter ended Sep 30, 2026, Ironwood Pharmaceuticals reported EPS of $0.36, above the $0.30 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
IRWD has an expected report date of Feb 23, 2027.
IRWD Earnings Call
The latest IRWD earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 39 quarters below that had an estimate, IRWD beat 20, missed 18 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $133.04M, up 9.0% from $122.06M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.36 | $0.30 | $0.30 - $0.32 | +20.00% | Beat | +50.0% | 2 | 1 up, 0 down | Nov 5, 2026 | $133.04M |
| Jun 30, 2026 | $0.31 | $0.26 | N/A | +19.23% | Beat | +121.4% | 2 | 0 up, 1 down | Aug 6, 2026 | $113.04M |
| Mar 31, 2026 | $0.24 | $0.24 | $0.13 - $0.38 | 0.00% | In line | N/A | 3 | 2 up, 0 down | May 7, 2026 | $106.51M |
| Dec 31, 2025 | -$0.01 | $0.02 | N/A | -159.52% | Miss | -150.0% | 2 | 0 up, 2 down | Feb 25, 2026 | $47.71M |
| Sep 30, 2025 | $0.24 | $0.12 | $0.09 - $0.14 | +100.00% | Beat | +1100.0% | 2 | 1 up, 1 down | Nov 10, 2025 | $122.06M |
| Jun 30, 2025 | $0.14 | -$0.02 | N/A | +800.00% | Beat | N/A | 2 | 1 up, 1 down | Aug 7, 2025 | $85.24M |
| Mar 31, 2025 | -$0.14 | -$0.03 | N/A | -366.67% | Miss | N/A | 1 | 0 up, 0 down | May 7, 2025 | $41.14M |
| Dec 31, 2024 | $0.02 | $0.08 | $0.03 - $0.16 | -74.19% | Miss | N/A | 4 | 0 up, 0 down | Feb 27, 2025 | $90.55M |
| Sep 30, 2024 | $0.02 | $0.10 | $0.01 - $0.18 | -80.00% | Miss | -83.3% | 5 | 0 up, 0 down | Nov 7, 2024 | $91.59M |
| Jun 30, 2024 | -$0.01 | $0.14 | $0.10 - $0.21 | -103.86% | Miss | N/A | 6 | 0 up, 0 down | Aug 8, 2024 | $94.40M |
| Mar 31, 2024 | -$0.02 | $0.15 | $0.10 - $0.48 | -113.33% | Miss | -108.0% | 6 | 0 up, 0 down | May 9, 2024 | $74.88M |
| Dec 31, 2023 | -$0.01 | $0.20 | $0.13 - $0.39 | -105.00% | Miss | -103.7% | 6 | 0 up, 0 down | Feb 15, 2024 | $117.55M |
| Sep 30, 2023 | $0.12 | $0.16 | $0.12 - $0.25 | -25.00% | Miss | -57.1% | 4 | 0 up, 0 down | Nov 9, 2023 | $113.74M |
| Jun 30, 2023 | -$6.71 | $0.25 | $0.23 - $0.26 | N/A | N/A | -3295.2% | 3 | 0 up, 0 down | Aug 8, 2023 | $107.38M |
| Mar 31, 2023 | $0.25 | $0.24 | $0.23 - $0.27 | +4.17% | Beat | +19.0% | 4 | 1 up, 1 down | May 4, 2023 | $104.06M |
| Dec 31, 2022 | $0.27 | $0.26 | $0.25 - $0.31 | +3.85% | Beat | 0.0% | 5 | 0 up, 2 down | Feb 16, 2023 | $107.20M |
| Sep 30, 2022 | $0.28 | $0.27 | $0.25 - $0.28 | +3.70% | Beat | -15.2% | 4 | 1 up, 0 down | Nov 3, 2022 | $108.64M |
| Jun 30, 2022 | $0.21 | $0.30 | $0.24 - $0.35 | -30.00% | Miss | -38.2% | 4 | 0 up, 0 down | Aug 4, 2022 | $97.23M |
| Mar 31, 2022 | $0.21 | $0.26 | $0.22 - $0.27 | -19.23% | Miss | -12.5% | 4 | 0 up, 1 down | May 5, 2022 | $97.53M |
| Dec 31, 2021 | $0.27 | $0.34 | $0.32 - $0.38 | -20.59% | Miss | -25.0% | 4 | N/A | Feb 17, 2022 | $117.13M |
| Sep 30, 2021 | $0.33 | $0.32 | $0.28 - $0.33 | +3.13% | Beat | +43.5% | 5 | N/A | Nov 4, 2021 | $103.75M |
| Jun 30, 2021 | $0.34 | $0.22 | $0.21 - $0.25 | +54.55% | Beat | +112.5% | 5 | N/A | Aug 5, 2021 | $104.03M |
| Mar 31, 2021 | $0.24 | $0.22 | $0.12 - $0.33 | +9.09% | Beat | +500.0% | 5 | N/A | May 6, 2021 | $88.84M |
| Dec 31, 2020 | $0.36 | $0.29 | $0.22 - $0.37 | +24.14% | Beat | +20.0% | 5 | N/A | Feb 17, 2021 | $116.68M |
| Sep 30, 2020 | $0.23 | $0.15 | $0.11 - $0.17 | +53.33% | Beat | -42.5% | 5 | N/A | Nov 5, 2020 | $103.47M |
| Jun 30, 2020 | $0.16 | $0.10 | $0.03 - $0.11 | +60.00% | Beat | +60.0% | 6 | N/A | Aug 6, 2020 | $89.43M |
| Mar 31, 2020 | $0.04 | $0.05 | -$0.03 - $0.12 | -20.00% | Miss | N/A | 5 | N/A | May 6, 2020 | $79.94M |
| Dec 31, 2019 | $0.30 | $0.24 | $0.13 - $0.30 | +25.00% | Beat | N/A | 7 | N/A | Feb 13, 2020 | $126.30M |
| Sep 30, 2019 | $0.40 | $0.12 | $0.06 - $0.19 | +233.33% | Beat | N/A | 7 | N/A | Oct 31, 2019 | $131.17M |
| Jun 30, 2019 | $0.10 | -$0.02 | -$0.19 - $0.06 | +600.00% | Beat | N/A | 7 | N/A | Jul 30, 2019 | $102.22M |
| Mar 31, 2019 | -$0.26 | -$0.23 | -$0.27 - $0.10 | -13.04% | Miss | N/A | 7 | N/A | May 2, 2019 | $68.73M |
| Dec 31, 2018 | -$0.02 | -$0.19 | -$0.21 - $0.00 | +89.47% | Beat | N/A | 7 | N/A | Feb 13, 2019 | $130.69M |
| Sep 30, 2018 | -$0.38 | -$0.20 | -$0.21 - -$0.13 | -90.00% | Miss | N/A | 7 | N/A | Nov 6, 2018 | $65.69M |
| Jun 30, 2018 | -$0.28 | -$0.23 | -$0.27 - -$0.10 | -21.74% | Miss | N/A | 9 | N/A | Aug 6, 2018 | $81.11M |
| Mar 31, 2018 | -$0.27 | -$0.23 | -$0.29 - -$0.18 | -17.39% | Miss | N/A | 7 | N/A | May 1, 2018 | $69.16M |
| Dec 31, 2017 | -$0.14 | -$0.20 | -$0.25 - -$0.16 | +30.00% | Beat | N/A | 7 | N/A | Feb 15, 2018 | $94.21M |
| Sep 30, 2017 | -$0.18 | -$0.24 | -$0.29 - -$0.14 | +25.00% | Beat | N/A | 10 | N/A | Nov 2, 2017 | $86.83M |
| Jun 30, 2017 | -$0.28 | -$0.23 | -$0.31 - -$0.15 | -21.74% | Miss | N/A | 11 | N/A | Aug 3, 2017 | $65.08M |
| Mar 31, 2017 | -$0.33 | -$0.21 | N/A | -57.14% | Miss | N/A | N/A | N/A | May 8, 2017 | $52.17M |
| Dec 31, 2016 | -$0.09 | -$0.24 | N/A | +62.50% | Beat | N/A | N/A | N/A | Feb 21, 2017 | $87.46M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.23, up 1475.3% from the year before. It was -$0.51 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.23 | +1475.3% |
| Dec 31, 2024 | $0.01 | N/A |
| Dec 31, 2023 | -$6.35 | -754.6% |
| Dec 31, 2022 | $0.97 | -17.8% |
| Dec 31, 2021 | $1.18 | +49.4% |
| Dec 31, 2020 | $0.79 | +46.3% |
| Dec 31, 2019 | $0.54 | N/A |
| Dec 31, 2018 | -$0.95 | N/A |
| Dec 31, 2017 | -$0.93 | N/A |
| Dec 31, 2016 | -$0.51 | N/A |
Earnings Calls
The 7 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 3,700 words across 9 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 3,726 | 9 | |
| 2026Q2 | Jun 30, 2026 | 4,375 | 11 | |
| 2026Q1 | Mar 31, 2026 | 4,399 | 10 | |
| 2025Q4 | Dec 31, 2025 | 4,692 | 10 | |
| 2024Q4 | Dec 31, 2024 | 4,147 | 9 | |
| 2024Q3 | Sep 30, 2024 | 3,448 | 8 | |
| 2024Q2 | Jun 30, 2024 | 4,367 | 11 |
2026Q3 Earnings Call
Opening remarks
Chris Stamm VP of Investor Relations and Communications Good morning, and thanks for joining our third quarter 2026 investor update call. A press release issued this morning highlighting third quarter results can be found on our website. Today's call and accompanying slides include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially. A discussion of these statements and risk factors is available on the current safe harbor statement slide, as well as under the heading Risk Factors in our annual report on Form 10-K for the year ended December 31, 2025, and in our subsequent SEC filings. All forward-looking statements speak as of the date of this presentation, and we undertake no obligation to update such statements. Also included are non-GAAP financial measures, which should be considered only as a supplement to, and not a substitute for or superior to, GAAP measures. To the extent applicable, please refer to the tables at the end of our press release for reconciliations of these measures to the most directly comparable GAAP measures. During today's call, Chief Executive Officer Tom McCourt will review third quarter business highlights and our progress advancing our 2026 strategic priorities. Following Tom, Chief Commercial Officer and CEO-elect Tammi Gaskins will provide an overview of third quarter LINZESS performance. Next, Jeff Silber, our Chief Medical Officer and Head of Research and Drug Development, will provide an update on apraglutide and the STARS-2 trial. Ron Silver, our Interim Chief Financial Officer, will provide a financial update before turning the call back to Tom and Tammi for some closing remarks prior to opening the call for questions. Jeff Ruberti, Ironwood's Chief Strategy Officer, will also be available during the Q&A portion of the call. Today's webcast includes accompanying slides. For those joining by phone, please visit the Events section of our website to access the presentation. With that, I'll turn the call over to Tom.
Tom McCourt CEO Thanks, Chris, and thank you all for joining us this morning to review Ironwood's third quarter 2026 financial results and business updates. Ironwood's momentum carried into the third quarter as we continued our focused execution across three strategic priorities: maximizing the value of LINZESS, advancing the development of apraglutide, and delivering sustained profits and cash flow. 2026 continues to be a turnaround year for the company as we make meaningful progress across each of these priorities. We believe LINZESS is on its way to returning to blockbuster status this year, demonstrating exceptional durability and growth in its 14th year on the market and remaining the leading U.S. branded prescription therapy for both IBS-C and chronic constipation.
Frequently Asked Questions About IRWD
When is Ironwood Pharmaceuticals's next earnings date?
Ironwood Pharmaceuticals's next earnings report is expected for Feb 23, 2027.
Did IRWD beat earnings estimates last quarter?
Yes. Ironwood Pharmaceuticals reported EPS of $0.36 for the quarter ended Sep 30, 2026, above the $0.30 estimate, a 20.00% surprise.
What EPS do analysts expect from IRWD next quarter?
The consensus EPS estimate for Ironwood Pharmaceuticals for the quarter ending Dec 31, 2026 is $0.37 from 6 analysts, with estimates from $0.33 to $0.41.
How often does IRWD beat earnings estimates?
Ironwood Pharmaceuticals beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +42.36%.
IRWD pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors